Liver and the Spleen Stifness in Adult Patients With Gaucher's Disease Using Ultrasound Shear Wave Elastography
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03896607|
Recruitment Status : Recruiting
First Posted : April 1, 2019
Last Update Posted : August 7, 2019
|Condition or disease|
|Gaucher Disease Liver Fibrosis Spleen; Fibrosis|
To assess liver and spleen stiffness measurement using Shear Wave Elastography-SWE and evaluate liver and spleen fibrosis in patients with Gaucher Disease. To compare the elastography with the biomarkers that taken at the GD haematology clinic and to check the correlation with severity of liver and spleen fibrosis.
SWE is a safe with diagnostic accuracy regarding the liver (& Spleen) fibrosis. Estimating spleen fibrosis is an innovative approach in liver disease and Gaucher.
The evaluation of fibrosis with this relatively new and safe method could avoid complications and invasive procedure in GD patients .
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Prospective Study: Shear-Wave Elastography of the Liver and the Spleen in Adult Patients With Gaucher's Disease|
|Actual Study Start Date :||March 30, 2019|
|Estimated Primary Completion Date :||November 1, 2019|
|Estimated Study Completion Date :||December 1, 2019|
- Shear Wave Elastography of liver to asses liver fibrosis in Gaucher disease patients. [ Time Frame: 0-2 hours ]Shear wave elastography(SWE),an ultrasound imaging technique that can produce 2D and 3D images and quantified measurements of tissue stiffness noninvasively. SWE obtained from the right liver lobe for staging liver fibrosis according to Metavir Fibrosis Score with sensitivity86%-98% and specificity 90%-93%. SWE well corelated with Metavir Fibrosis Score which is system used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy. The biomarkers of disease severity will be correlated to METAVIR score. METAVIR score(F0-F4) ,Fibrosis Level measured by KPa(kiloPascal) using SWE. F0 = Below 5 KPa, No fibrosis. F1=5.0-7.1 KPa, Mild Fibrosis. F2=7.1-8.7 KPa, Significant Fibrosis. F3=8.7-10.4 KPa, Sever Fibrosis. F4=10.4-19 KPa ,Cirrhosis. SWE can differentiate patients with no or minimal (F0 and F1) fibrosis from those with severe fibrosis or cirrhosis (F3 and F4) with no need for biopsy unless there are other factors that need to be considered.
- Shear Wave Elastography of spleen to asses spleen fibrosis in Gaucher disease patients. [ Time Frame: 0-2 hours ]
Shear wave elastography (SWE), an ultrasound imaging technique that can produce 2D and 3D images and quantified measurements of tissue stiffness noninvasively.
Participants with Gaucher disease will under go shear wave elastography for spleen.
Ultrasound Elastography is a non-invasive test which uses the technology of Shear Wave Elastography (SWE) obtained from the spleen for staging tissue fibrosis according to a study, Spleen Elastography was performed in 59 healthy individuals and the mean value measured in KPa (kiloPascal) was 16.6 ± 2.5 kPa, independent of patient age, sex or spleen size.
above the normal value it is considerd fibrosis of the tisuue of the spleen.
- Biomarkers of the Gaucher Disease [ Time Frame: Up to 1 month ]
Gaucher Disease (GD) patients will be referred from the (GD) hematology outpatient clinic, in different patients different biomarker are already taken (as blood test).
Biochemical abnormalities which might be already taken from patients, for example; blood level of ferritin (unit: ng/mL), angiotensin converting enzyme (unit: kU/L), chitotriosidase (unit: U/L) and polyclonal immunoglobulins (unit: ng/dL) .
Elevated biomarkers can predict the severity of the disease.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03896607
|Contact: Ziv Neeman, MDfirstname.lastname@example.org|
|Contact: Rayiq Wisam Shajrawi, MDemail@example.com|
|HaEmek Medical Center||Recruiting|
|Afula, Tsafon, Israel, 1834111|
|Contact: ziv neeman, MD +972584988466 firstname.lastname@example.org|
|Contact: Rayiq Wisam Shajrawi, MD +972524234067 email@example.com|
|Principal Investigator:||ziv neeman, MD||haemek medical center|